$ALIT

Alight, Inc. / Delaware (ALIT) filed an SEC Form 8-K — Regulation FD Disclosure. Item 7.01 Regulation FD Disclosure. Alight, Inc. (the “Company” or “Alight”) has been engaged in confidential discussions with certain lenders (collectively, the “Lenders”) and their financial and legal advisers regarding potential refinancing and/or extension opportunities (a “P

D.A. Davidson reiterated a Buy rating and $22 price target for Alight Solutions (ALIT), citing its acquisition of Abett. The stock trades near its 52-week low at $8.72. Alight reported Q2 2026 adjusted earnings of $0.91 per share on revenue of $511M, missing EPS estimates but exceeding revenue expectations. The firm lowered its target from $32 due to higher customer attrition concerns.

Alight, Inc. (ALIT) acquired Abett, a healthcare and benefits data technology company. The deal aims to strengthen Alight's benefits data platform, though financial terms were not disclosed.

ManpowerGroup reported Q2 revenue of $4.86B, up 7.5% YoY, beating estimates. Its stock is up 46% since reporting. Barrett (BBSI) reported $319.3M in revenue, up 3.8% YoY, missing EPS estimates, and its stock is down 21.2%. Alight (ALIT) reported $511M in revenue, down 3.2% YoY, beating expectations but missing guidance, and its stock is down 33.3%. First Advantage (FA) reported $448.8M in revenue, up 14.9% YoY, beating estimates, and its stock is down 3.1%.

Ultragenyx (RARE) and Regeneron (REGN) received FDA approvals for GENGLYCOS and Pasatru, respectively. BioMarin (BMRN) acquired Alesta for $490M. Humacyte (HUMA) and Eyepoint (EYPT) faced trial setbacks. Key financials: RARE -$25.32, REGN -$826.64, BMRN -$67.68, HUMA -$0.68.

Alight (ALIT) said it partnered with Spring Health to integrate Spring Health’s AI-native mental health services into the Alight Worklife benefits platform. The platform supports over 210 million annual interactions. Alight said the goal is earlier access during events like open enrollment and leave. JAMA Network Open research cited faster recovery for Spring Health members.

Alight (NYSE:ALIT) reported Q2 revenue of $511 million, beating Wall Street expectations, with adjusted EBITDA of $92 million and free cash flow above estimates. However, recurring revenue fell 4.3% and adjusted EPS dropped to $0.91 from $2.09. Q3 guidance calls for $469 million to $479 million revenue and adjusted EBITDA of $55 million to $61 million.

Alight (NYSE: ALIT) shares fell about 17% after the company issued weak forward guidance. Although its second-quarter revenue and adjusted profitability beat expectations, investors focused on a 3.2% year-over-year sales decline and a third-quarter revenue outlook about 5.5% below analyst estimates, with a midpoint of $2.09 billion. Full-year revenue and adjusted EBITDA forecasts also missed consensus.

Alight (NYSE: ALIT) reported Q2 CY2026 revenue of $511 million, down 3.2% year on year but above Wall Street expectations, and non-GAAP EPS of $0.91, 20% above consensus. Next-quarter revenue guidance was $474 million, 5.5% below estimates. Management cited stronger project revenue, but recurring revenue and renewals remain pressured.

Alight (NYSE:ALIT) reported Q2 CY2026 revenue of $511 million, down 3.2% year on year but 2.8% above Wall Street estimates. Non-GAAP EPS was $0.91, up 20% versus consensus. Guidance for next quarter revenue was $474 million, 5.5% below estimates, and the stock fell 9.1% to $15.58.